Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC00240 antisense RNA regulating promoter methylation (LARRPM) is a 954-nucleotide long, polyadenylated long non-coding RNA transcribed from the locus LOC100270746 on chromosome 6p22.2, oriented antisense to the LINC00240 gene. LARRPM acts as a regulator of local DNA methylation by binding and recruiting the DNA demethylase TET1 to the LINC00240 promoter, resulting in demethylation and increased transcription of LINC00240. Functionally, LARRPM exhibits tumor-suppressive activity in lung adenocarcinoma cells by inhibiting their proliferation, migration, and invasion, while promoting apoptosis. Furthermore, LARRPM reduces the recruitment and polarization of M2-type tumor-associated macrophages in the tumor microenvironment, thereby enforcing an anti-tumor immune milieu. Low LARRPM levels are correlated with advanced tumor stage and worse survival outcomes in lung adenocarcinoma. The gene is classified as an lncRNA and has no protein-coding potential. There are currently no drugs or small molecules directly targeting LARRPM, but it is being studied for its biomarker and therapeutic target potential in cancer biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LINC00240 antisense RNA regulating promoter methylation (LARRPM).